Polaris AS (Targovax AS)

Targovax is an Oslo-area based global biotechnology company, dedicated to the design and development of immunotherapy vaccines for patients with RAS-mutated cancers. Established in 2010 by the inventors of this RAS-targeted technology and the Norwegian Radium Hospital Research Foundation in Oslo, Targovax has over 25 years of direct experience and has seen more than 250 patients treated with this promising technology. *

	Start	2015-06-11 merged
	Group	Polaris (NO) (Group)
	Predecessor	Targovax ASA (OSE: TRVX)
	Industry	TG01 (Targovax)
	Industry 2	therapeutic vaccine
	Person	Gårdemyr, Gunnar (Follicum 201902 before Targovax/Polaris + Nycomed/Takeda)
	Person 2	Øystein, Soug (Polaris 201506 announced as CFO before Algeta + Orcla)

	Region	Lysaker
	Country	Norway
	City	n. a.
		Address record changed: 2015-06-21

Basic data	Employees	B: 11 to 50 (2015-06-11)

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)